Civica Partners With Phlow To Build $125m Injectables Facility In US

Operations Expected To Begin Within Three Years

Lauding a “dream come true,” Civica has announced plans to build its own injectables manufacturing facility via a strategic partnership with fellow public health firm Phlow Corporation.

Strategy
Building US manufacturing space has been a part of Civica’s supply strategy since it was founded in 2018 • Source: Shutterstock

Non-profit generics manufacturer Civica Rx says it will invest $124.5m with strategic partner Phlow Corporation to build a 120,000 sq ft (11,150 sq m) sterile injectable manufacturing facility in Petersburg, Virginia, for production of essential medicines, including those used in hospitals for the treatment of COVID-19.

With construction already underway, Civica expects to begin operations within three years. “A talented, highly experienced plant leadership team is...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business